Novin AgriTech, a Purdue University spinoff, just became the first wheat biotech company to receive federal Small Business Innovation Research funding specifically for nitrogen use efficiency trait development using a transformation method that avoids the tissue culture step entirely. The award: $174,906 from the USDA's National Institute of Food and Agriculture, an eight-month Phase I contract dated May 6, 2026. The stakes are not immediately obvious from the numbers, but they should be. Wheat transformation has been locked behind a technical gate for two decades, and this contract is an attempt to kick it open.
Why this matters: wheat is the world's third-most-consumed crop after rice and corn, and it is also the one where genetic improvement has moved slowest. Corn and soybean breeders have benefited from decades of transformation and gene-editing infrastructure. Wheat breeders still mostly use conventional crossing and selection because traditional tissue culture-based transformation is slow, expensive, and fails on the elite germplasm that farmers actually grow. You end up with a well-edited wheat plant that nobody wants to farm. Novin AgriTech's co-founder Mohsen Mohammadi developed two patented platforms, InPACT (the core technology) and a nanoparticle-assisted ultrasound gene delivery system, that bypass tissue culture entirely. Instead of growing callus in a petri dish, you transform the seed or seedling directly, in the genotype you care about. The technology exists. The question has been whether it could scale to a real commercial trait on real farm-ready varieties. That is exactly what this SBIR award is designed to answer.
The contract is structured as technical validation on a single, commercially critical trait: nitrogen use efficiency (NUE) in elite wheat cultivars. Novin will spend eight months proving that InPACT can deliver a heritable NUE improvement in wheat varieties that farmers would actually plant. The company has also established a Cooperative Research and Development Agreement (CRADA) with the USDA Agricultural Research Service, which provides access to germplasm and field infrastructure. Mohammadi, who leads Purdue's soft red winter wheat breeding program, has existing relationships with USDA breeders and regulatory pathways, institutional advantages that matter when you are trying to move a trait from Phase I validation to field trials and regulatory positioning. The SBIR covers eight months. If successful, the same workflow scales rapidly to barley, oats, and sorghum, and to other traits like Fusarium head blight resistance and abiotic stress tolerance.
Why now: the USDA has been under sustained pressure to fund crop biotechnology alternatives to traditional transgenics, partly because gene-editing markets like the EU restrict some traits, and partly because yield gains from conventional breeding have plateaued. Wheat specifically has become a symbolic crop, if the U.S. government can demonstrate a non-GMO, gene-editing-compatible pathway to rapid trait deployment, it opens markets (like some EU countries and Japan) where full-transgenic wheat is still politically toxic. Novin's tissue culture-free approach is not gene editing, but it is compatible with gene editing downstream. The timing also reflects capital flight: venture funding for agtech has contracted since 2022, and the SBIR program is one of the few reliable sources of early-stage validation capital for crop science. Novin likely would not have raised $175K easily in the current VC environment.
What this means: Novin AgriTech is now the first mover in a segment that has been starved for investment, trait engineering for wheat using modern transformation platforms. If the company succeeds, it chips away at the competitive moat that corn and soybean companies have built over 20 years. Existing seed companies (Corteva, Bayer, BASF) have tissue culture infrastructure and germplasm libraries, but they are also locked into R and D cycles measured in decades. A nimble startup that can transform elite wheat directly, validate a trait in eight months, and hand it off to a seed partner for regulatory approval and commercialization, could compress that cycle to three to five years. That is a threat to the incumbents' timeline advantage, not their market share, at least not yet. Farmers do not yet know if they want NUE wheat, or if the economics pencil out. But the USDA is betting that the bottleneck is transformation speed, not trait validity. If it is right, Novin becomes a platform play, not a one-trait company.
What to watch: first, whether Novin delivers a heritable, agronomically viable NUE trait in wheat by month eight. That is the gate. Second, whether the company pursues a Phase II SBIR contract (another $750K–$1.5M typically, 24-month runway) to move from lab validation to field trials. That decision will signal whether the team believes the platform actually works at scale. Third, whether a seed company signs a trait license or commercialization agreement within 12 months of Phase I completion. That is when you will know if the tissue culture-free platform has real commercial traction, or if it remains a nice idea with limited uptake.